Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 4/20 | 0.51 |
| ▸ | NPY2R | P49146 | 7/20 | 0.49 |
| ▸ | NPY4R | P50391 | 7/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.49 |
| ▸ | NPY1R | P25929 | 5/20 | 0.49 |
| ▸ | CALCR | P30988 | 3/20 | 0.49 |
| ▸ | NTSR1 | P30989 | 2/20 | 0.48 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29756030 | 0.98 | NTSR1 (0.50) | F2NPY2RNPY4RNPY5RNTSR1 | |
| SCHEMBL30020318 | 0.87 | MAPK8 (0.53) | F2NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29611574 | 0.87 | CAPN1 (0.50) | NTSR1 | |
| SCHEMBL30906472 | 0.86 | EP300 (0.54) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL30648484 | 0.85 | CALCR (0.62) | F2NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30880882 | 0.85 | CALCR (0.55) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL29611631 | 0.85 | NTSR1 (0.50) | NTSR1 | |
| SCHEMBL30432281 | 0.84 | CALCR (0.60) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL31031609 | 0.84 | NPY2R (0.54) | NPY2RNPY4RNPY5RNPY1RCALCR | |
| SCHEMBL8937114 | 0.84 | NPY2R (0.58) | NPY2RNPY4RNPY5RNPY1RCALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737561-A2 | PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF | Juno Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4051402-B1 | CELL SELECTION AND/OR STIMULATION DEVICES AND METHODS OF USE | C3S2 GMBH (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-20260078165-A1 | PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF | JUNO THERAPEUTICS, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-12522660-B2 | Methods for selection and stimulation of cells and apparatus for same | C3S2 GMBH (DE) | 2026-01-13 | — | — | US | disclosed |
| EP-4647493-A2 | OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF | Juno Therapeutics, Inc. (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250283037-A1 | METHODS FOR STIMULATING AND TRANSDUCING T CELLS | JUNO THERAPEUTICS GMBH (DE) | 2025-09-11 | — | — | US | disclosed |
| US-20250237628-A1 | CELL SELECTION AND/OR STIMULATION DEVICES AND METHODS OF USE | JUNO THERAPEUTICS GMBH (DE) | 2025-07-24 | — | — | US | disclosed |
| EP-3615653-B1 | OLIGOMERIC PARTICLE REAGENTS AND METHODS OF USE THEREOF | JUNO THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-4545964-A2 | CHROMATOGRAPHIC ISOLATION OF CELLS AND OTHER COMPLEX BIOLOGICAL MATERIALS | Juno Therapeutics GmbH (DE) | 2025-04-30 | — | — | EP | disclosed |
| EP-4180811-B1 | METHODS OF ISOLATING A BIOLOGICAL ENTITY | CELL COPEDIA GMBH (DE) | 2025-04-09 | — | — | EP | disclosed |
| WO-2022234009-A2 | METHODS FOR STIMULATING AND TRANSDUCING T CELLS | JUNO THERAPEUTICS GMBH (DE) | 2022-11-10 | — | — | WO | disclosed |
| EP-4004545-B1 | METHODS OF ISOLATING A BIOLOGICAL ENTITY | CELL COPEDIA GMBH (DE) | 2022-11-02 | — | — | EP | disclosed |
| US-11466253-B2 | Methods for culturing cells and kits and apparatus for same | JUNO THERAPEUTICS GMBH (DE) | 2022-10-11 | — | — | US | disclosed |
| EP-4051402-A1 | CELL SELECTION AND/OR STIMULATION DEVICES AND METHODS OF USE | Juno Therapeutics GmbH (DE) | 2022-09-07 | — | — | EP | disclosed |
| CN-114929360-A | Cell selection and/or stimulation devices and methods of use | 朱诺治疗学有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220243223-A1 | METHODS, KITS, AGENTS AND APPARATUSES FOR TRANSDUCTION | JUNO THERAPEUTICS GMBH (DE) | 2022-08-04 | — | — | US | disclosed |
| US-20220195388-A1 | METHODS, KITS AND APPARATUS FOR EXPANDING A POPULATION OF CELLS | JUNO THERAPEUTICS GMBH (DE) | 2022-06-23 | — | — | US | disclosed |
| EP-3988920-A1 | METHODS, KITS AND APPARATUS FOR EXPANDING A POPULATION OF CELLS | Juno Therapeutics GmbH (DE) | 2022-04-27 | — | — | EP | disclosed |
| US-11274278-B2 | Methods, kits and apparatus for expanding a population of cells | JUNO THERAPEUTICS GMBH (DE) | 2022-03-15 | — | — | US | disclosed |
| US-11248238-B2 | Methods, kits, agents and apparatuses for transduction | JUNO THERAPEUTICS GMBH (DE) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078165-A1 | PROCESSES FOR GENERATING ENGINEERED CELLS AND COMPOSITIONS THEREOF | CD4, CD69, ICOS | F2 2172/4885NPY2R 4152/4885NPY4R 4278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.